Heart Valve Repair
Carpentier-Edwards Physio II
Carpentier-Edwards Physio
Cosgrove-Edwards
Myxo ETlogix
GeoForm
IMR ETlogix
Edwards MC3
Carpentier-Edwards Classic
Related Products

Request Information
Technical Information

For Patients

Heart Valve News
Report from NPR
2006 ACC / AHA Guidelines

Heart Valve Education
Myxo ETlogix Ring
Mitral valve repair is the gold standard1
In patients with an average age of 56 years, mitral valve repair restores the normal survival curve while avoiding the limitations of mechanical valve replacement.

Excess leaflet tissue associated with myxomatous disease
Myxomatous disease is characterized by elongated, thickened leaflets that result in leaflet billowing, annular dilatation, ruptured chords and mitral regurgitation (MR).2

Move instead of remove
The Myxo ETlogix ring moves the posterior leaflet inferiorly thereby reducing the reconstruction required to decrease the posterior leaflet height.3

Mitigate SAM and LVOTO
Extends the posterior leaflet up and away from the left ventricular outflow tract (LVOT) mitigating systolic anterior motion (SAM) and LVOTO with less leaflet reconstruction.3

Designed for ease of use
See cut away view and image of holder
  • Robust silicone sewing margin designed for effortless needle placement
  • Polyester velour cloth chosen to ensure smooth suture slide
  • Specially designed holder simplifies visualization of the restored coaptation line
  • Rigid titanium core reshapes the annulus to accommodate excess leaflet tissue


References:
1. Braunberger E, et al. Very long-term results (more than 20 years) of valve repair with Carpentier's techniques in nonrheumatic mitral valve insufficiency. Circulation. 2001;104(12 Suppl 1):I8-11.
2. Perier P, et al. Valve repair for mitral regurgitation caused by isolated prolapse of the posterior leaflet. Ann Thorac Surg 1997;64(2):445-50.
3. Maslow AD, et al. Echocardiographic predictors of left ventricular outflow tract obstruction and systolic anterior motion of the mitral valve after mitral valve reconstruction for myxomatous valve disease. J Am C Cardio 1999;34(7):2096-104.

See instructions for use for full prescribing information.

Animation
Implantation Video
Case Presentation
Model
Accessories
Contact Us | Legal Terms | Privacy Policy | © 2010 Edwards Lifesciences LLC. All rights reserved.